Issue
Med Sci (Paris)
Volume 40, Number 6-7, Juin-Juillet 2024
Nos jeunes pousses ont du talent !
Page(s) 581 - 583
Section Partenariat médecine/sciences - Écoles doctorales - Masters
DOI https://doi.org/10.1051/medsci/2024076
Published online 08 July 2024
  1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018 ; 359 : 1350–1355. [Google Scholar]
  2. Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy. Annu Rev Immunol 2001 ; 19 : 565–594. [CrossRef] [PubMed] [Google Scholar]
  3. Morad G, Helmink BA, Sharma P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 2021; 184 : 5309–37. [CrossRef] [PubMed] [Google Scholar]
  4. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov 2018 ; 8 : 1069–1086. [CrossRef] [PubMed] [Google Scholar]
  5. Allenbach Y, Anquetil C, Manouchehri A, et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 2020; 19 : 102586. [CrossRef] [PubMed] [Google Scholar]
  6. Salem J-E, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018 ; 19 : 1579–1589. [CrossRef] [PubMed] [Google Scholar]
  7. Wei SC, Meijers WC, Axelrod ML, et al. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discov 2021; 11 : 614–25. [CrossRef] [PubMed] [Google Scholar]
  8. Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med 2021; 385 : 228–38. [CrossRef] [PubMed] [Google Scholar]
  9. Pinal-Fernandez I, Quintana A, Milisenda JC, et al. Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis. Ann Rheum Dis 2023; 82 : 829–36. [CrossRef] [PubMed] [Google Scholar]
  10. Salem JE, Bretagne M, Abbar B, et al. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discov 2023; 13 : 1100–15. [CrossRef] [PubMed] [Google Scholar]
  11. Latek R, Fleener C, Lamian V, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009 ; 87 : 926–933. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.